Monitor future earnings reports for UK subscriber growth and revenue contribution from the expanded CheqUp partnership. The NHS medication access expansion provides a supportive regulatory backdrop, but near-term financial impact is uncertain.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 17 $19.05entry
- T+1 · 5mo ago +0.79%α +0.01% · $19.20
- T+5 · 5mo ago −7.87%α −6.83% · $17.55
- T+20 · 4mo ago −21.94%α −23.26% · $14.87
- T+60 · 2mo ago −22.41%α −25.56% · $14.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
WW International (Weight Watchers) announced an expanded partnership with UK digital weight health platform CheqUp, integrating clinical and behavioral weight management for UK members. The collaboration allows Weight Watchers members to access CheqUp's medical weight loss consultations, while CheqUp members receive the Weight Watchers app and GLP-1 Companion Programme. This strategic move aligns with the NHS's recent expansion of weight-loss medication access, potentially driving UK member growth.
Key Facts
- Expanded partnership with CheqUp in the UK, making CheqUp the dedicated partner for weight-loss treatment.
- Weight Watchers members in the UK can access CheqUp consultations from the Weight Watchers website.
- CheqUp members continue to receive full access to the Weight Watchers app and GLP-1 Companion Programme.
- NHS recently expanded access to weight-loss medications to over a million people in England with heart health issues.
- 85% of GLP-1 Companion Programme U.S. members say Weight Watchers makes it easier to get healthy; 81% describe it as the perfect partner on their GLP-1 journey (based on customer survey).
Financial Impact
No financial terms disclosed; partnership could drive UK subscriber growth and revenue, but impact is unquantified.
Risk Factors
- Partnership may not materially boost revenue or member engagement.
- Competition in the UK weight management market remains intense.
- Execution risk in integrating clinical and behavioral services across platforms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312997 |
Track record
20 reports on WW
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +9.16% at T+20 after the Apr 3, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $9.46 Now $9.46 +0.00% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $10.84 Now $9.46 −12.73% settles Dec 15
- Nov 10, 20266d ago Insider Cluster Bullish 4/10 Entry $13.05 Now $9.46 −27.51% settles Dec 10
- Nov 5, 202611d ago 8-K Mixed 6/10 Entry $12.84 Now $9.46 −26.32% settles Dec 4
- Oct 13, 20264w ago SC 13G/A Bearish 4/10 Entry $14.27 to $13.05 Now $9.46 +33.71% ▲ +8.55% +7.28% vs SPY
- Sep 9, 20269w ago 8-K Neutral 4/10 Entry $14.94 to $15.08 Now $9.46 −36.68% ▲ +0.94% −1.01% vs SPY
- Aug 20, 202612w ago Insider Buy Bullish 5/10 Entry $15.71 to $16.39 Now $9.46 −39.78% ▲ +4.33% +4.85% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $13.34 to $15.71 Now $9.46 −29.09% ▲ +17.77% +14.14% vs SPY
- Jun 16, 202621w ago Press Release Bullish 5/10 Viewing Entry $19.05 to $14.87 Now $9.46 −50.34% ▼ −21.94% −23.26% vs SPY
- Jun 4, 202623w ago DEFA14A Neutral 5/10 Entry $17.27 to $16.31 Now $9.46 −45.21% ▼ −5.53% −4.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers